secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cadrenal Therapeutics, Inc. (CVKD)
CIK:        0001937993
Form:       8-K
Filed at:   2026-02-24T23:59:59+00:00
Accession:  0001213900-26-019606
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cadrenal Therapeutics Phase 2 HIT trial: primary endpoint missed, thrombotic events reduced >25%
--------------------------------------------------------------------------------

- Platelet count recovery (primary endpoint) did not differ between CAD-1005 and placebo arms.
- Thrombotic events: >75% in placebo vs 50% in CAD-1005 group (>25% absolute reduction).
- End-of-Phase 2 meeting with FDA scheduled for March 2026 to discuss Phase 3 path.
- CAD-1005 is the only 12-LOX inhibitor in clinical development worldwide.
- Trial concluded December 2025 after program transfer from Veralox Therapeutics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937993/000121390026019606/0001213900-26-019606-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937993/000121390026019606/ea0278072-8k_cadrenal.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-019606

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer